{"url_path":"/sec/acrv/8-k/2026-05-13/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1781174/0001193125-26-221626-index.html","accession_number":"0001193125-26-221626","cik":"0001781174","ticker":"ACRV","issuer_name":"Acrivon Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1781174/0001193125-26-221626-index.html","primary_entity_key":"0001781174","primary_entity_name":"Acrivon Therapeutics, Inc."},"word_count":81,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\nExhibit\n\nNumber\n\nDescription\n\n99.1\n\n[Press Release, dated May 13, 2026](acrv-ex99_1.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nAcrivon Therapeutics, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nMay 13, 2026\n\nBy:\n\n/s/ Peter Blume-Jensen\n\n \n\n \n\n \n\nName: Peter Blume-Jensen, M.D., Ph.D.\nTitle: President and Chief Executive Officer"}